For relapsed or refractory DLBCL patients, salvage treatment strategies include either CD20 or CD79b-directed antibodies or antibody-drug conjugates, CD19-directed antibodies, and CAR-T cells as well as bone marrow or peripheral blood stem cell transplantation [51,52,53,54,55,56,57]. The gene discussed is CD79B; the disease is diffuse large B-cell lymphoma.